Patent application number | Description | Published |
20110112052 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 05-12-2011 |
20130296303 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 11-07-2013 |
20140057924 | BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of IAP proteins and compositions containing the same are disclosed. Methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP proteins provides a benefit, like cancers, also are disclosed. | 02-27-2014 |
20140199234 | BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed. | 07-17-2014 |
20140256706 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed. | 09-11-2014 |
20140378680 | SPIRO-OXINDOLE MDM2 ANTAGONISTS - Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases. | 12-25-2014 |
20150246923 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS - The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: | 09-03-2015 |
20150299211 | MDM2 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of MDM2 and MDM2-related proteins and compositions containing the same are disclosed. Methods of using the MDM2 inhibitors in the treatment of diseases and conditions wherein inhibition of an interaction between p53 and MDM2 provides a benefit, like cancers, also are disclosed. | 10-22-2015 |
20150336994 | BCL-2/BCL-XL INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed. | 11-26-2015 |
Patent application number | Description | Published |
20080255197 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS - The present invention relates to compounds that bind to chemokine receptors, and having the formula | 10-16-2008 |
20090281308 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY - Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts. | 11-12-2009 |
20100105915 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS - Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCR4 receptor. | 04-29-2010 |
20100298366 | CHEMOKINE RECEPTOR BINDING COMPOUNDS - The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). | 11-25-2010 |
20120301427 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY - The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HW). | 11-29-2012 |
20150038509 | Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy - The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). | 02-05-2015 |
Patent application number | Description | Published |
20090099205 | Chemokine receptor binding compounds - The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). | 04-16-2009 |
20130296301 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc. | 11-07-2013 |
20140206665 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc. | 07-24-2014 |
20150218097 | GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of Formula (I) for inhibiting gh cosidases, prodrugs of the compounds, and pharmaceutical compositions comprising the compounds or prodrugs of the compounds. The invention also provides method of treating diseases and disorders related to deficiency or over-expression of O-gh coprotein 2-acetamido-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase), accumulation or deficiency of 2-acetamido-2-deoxy-β-D-glucopyranoside (O-GlcNAc). | 08-06-2015 |
20150218147 | GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 08-06-2015 |
20150274656 | GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 10-01-2015 |
20150299122 | GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 10-22-2015 |
Patent application number | Description | Published |
20130131044 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 05-23-2013 |
20140018309 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 01-16-2014 |
20140088028 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of formula (I) with substituents as specified in Claim | 03-27-2014 |
20140107044 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 04-17-2014 |
20140213584 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 07-31-2014 |
20140275022 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 09-18-2014 |
20140296205 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 10-02-2014 |
20150045346 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 02-12-2015 |
20150291620 | GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 10-15-2015 |
20160096858 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 04-07-2016 |
Patent application number | Description | Published |
20110237631 | Selective Glycosidase Inhibitors and Uses Thereof - The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcN Ac. | 09-29-2011 |
20120095033 | Selective Glycosidase Inhibitors and Uses Thereof - The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 04-19-2012 |
20140051719 | Selective Glycosidase Inhibitors and Uses Thereof - The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 02-20-2014 |
Patent application number | Description | Published |
20130036177 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR MANAGING SOCIAL INTERACTION HISTORIES - According to one aspect, the subject matter described herein includes a method for managing social interaction information. The method includes receiving first social interaction information associated with a user of a first over the top (OTT) service platform. The method also includes receiving second social interaction information associated with the user, the second social interaction information from a communications service platform distinct from the first OTT service platform. The method further includes generating, using the first social interaction information and the second social interaction information, consolidated social interaction information and providing the consolidated social interaction information to the user. | 02-07-2013 |
20130040633 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR MANAGING ASSOCIATIONS BETWEEN USERS IN MULTIPLE OVER-THE-TOP SERVICE PLATFORMS - According to one aspect, the subject matter described herein includes a method for managing associations between users in multiple over-the-top (OTT) service platforms. The method includes receiving a first message indicating an action associated with a first user in a first OTT service platform. The method also includes generating, based on the first message, a second message for performing a related action in a second OTT service platform. The method further includes communicating the second message to the second OTT service platform. | 02-14-2013 |
20130054701 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR MANAGING MULTIPLE PERSONAS WITHIN END USER APPLICATIONS - Methods, systems, and computer readable media for managing multiple personas within end user applications are disclosed. According to one method, a first profile definition defining a first persona through which a user accesses at least one social networking, OTT, or other hosted service and at least one trigger condition associated with the activation of the first persona is accessed. The method further includes determining a context for the user. The method further includes determining whether the context for the user satisfies the at least one trigger condition. In response to determining that the context satisfies the at least one trigger condition, the first persona is activated. | 02-28-2013 |
20130080538 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR AFFECTING USER ASSOCIATIONS IN OVER THE TOP (OTT) SERVICE PLATFORMS - According to one aspect, the subject matter described herein includes a method for affecting user associations in over the top (OTT) service platforms. The method includes receiving a first message for initiating associations or disassociations between a first user and a second user of over the top (OTT) service platforms. The OTT service platforms are controlled and operated by distinct entities. The method also includes determining, using at least one of information in the first message and stored information, the OTT service platforms in which associations are to be established or disestablished. The method further includes sending at least a second message for establishing or disestablishing an association between the first user and the second user in the OTT service platforms. | 03-28-2013 |
20130176895 | METHODS, SYSTEMS, AND NON-TRANSITORY COMPUTER READABLE MEDIA FOR CREATING AND MANAGING AD-HOC GROUPS LINKED TO AN EVENT AND SPANNING MULTIPLE MODES OF COMMUNICATION - A method for creating and managing ad-hoc groups linked to an event and spanning multiple modes of communication includes creating an ad-hoc group associated with an event. Available modes of communication are determined for each participant in the group. For each mode of communication, first information for contacting each participant is determined. Second information that serves as an alias for each participant is determined. A consolidated view of the available modes of communication with each of the participants in the group is provided using the aliases. | 07-11-2013 |
20150326525 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR MANAGING MULTIPLE PERSONAS WITHIN END USER APPLICATIONS - Methods, systems, and computer readable media for managing multiple personas within end user applications are disclosed. According to one method, a first profile definition defining a first persona through which a user accesses at least one social networking, OTT, or other hosted service and at least one trigger condition associated with the activation of the first persona is accessed. The method further includes determining a context for the user. The method further includes determining whether the context for the user satisfies the at least one trigger condition. In response to determining that the context satisfies the at least one trigger condition, the first persona is activated. | 11-12-2015 |